Yongtai raises $4.73M in placement as key drug faces 39-month delay
What's the deal? Beijing Yongtai Biological ProductsDealroom has a profile for this one. Try Dealroom → (HK: 6978), a Chinese cell immunotherapy developer, is raising about US$4.48M (roughly $4.73 million) by placing new shares under a general mandate. It will issue 123,500,160 shares — about 20% of existing capital — at a minimum price of US$0.04, with Maishi Asset Management acting as placing agent.
Where the money goes: Net proceeds of about US$4.36M will fund research on its core EAL product, other pipeline and early-stage projects, and general corporate purposes. Roughly 60% is earmarked for EAL and other R&D, with the remainder for working capital.
Why now? China's Center for Drug Evaluation did not accept Yongtai's conditional marketing application for EAL, leaving the company to first settle a confirmatory trial design with regulators. It expects that trial to start in the first quarter of 2027, with resubmission some 39 months later.
The fine print: The placement price marks a discount of about 13% to the previous close of US$0.04 and about 18.3% to the five-day average. The new shares will dilute existing holders, representing 16.7% of enlarged capital once completed.
What could go wrong? This is a quick re-raise against a lengthening approval timeline. Yongtai netted about US$30.5M from a rights issue last year and had already spent about US$28.5M of it by the end of September 2026; a separate US$37.1M convertible bond this year went to repaying old debt, not new research. With most of the earlier cash used and EAL's path stretched out, the placement reads as a cash top-up rather than a sign of clinical progress.
The signal: For a clinical-stage biotech, returning to market at a discount to plug near-term funding gaps underscores how regulatory delays can quietly drain balance sheets long before a product reaches approval.
Read more: sohu.com
Image credit: Generated with Gemini
